EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines

The first approved COVID‐19 vaccines include Pfizer/BioNTech BNT162B2, Moderna mRNA‐1273 and AstraZeneca recombinant adenoviral ChAdOx1‐S. Soon after approval, severe allergic reactions to the mRNA‐based vaccines that resolved after treatment were reported. Regulatory agencies from the European Unio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Allergy
Hauptverfasser: Sokolowska, Milena, Eiwegger, Thomas, Ollert, Markus, Torres, Maria J., Barber, Domingo, Del Giacco, Stefano, Jutel, Marek, Nadeau, Kari C., Palomares, Oscar, Rabin, Ronald L., Riggioni, Carmen, Vieths, Stefan, Agache, Ioana, Shamji, Mohamed H.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2021
Schlagworte:
Eaaci Position Papers
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8013422/
https://ncbi.nlm.nih.gov/pubmed/33452689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.14739
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge